- Home
- AIRT vs ABVC Comparison
AIRT vs ABVC Comparison
Compare AIRT & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ABVC
- Stock Information
- Founded
- AIRT 1980
- ABVC 2015
- Country
- AIRT United States
- ABVC United States
- Employees
- AIRT N/A
- ABVC N/A
- Industry
- AIRT Air Freight/Delivery Services
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- ABVC Health Care
- Exchange
- AIRT Nasdaq
- ABVC Nasdaq
- Market Cap
- AIRT 59.0M
- ABVC 52.1M
- IPO Year
- AIRT N/A
- ABVC N/A
- Fundamental
- Price
- AIRT $22.05
- ABVC $3.30
- Analyst Decision
- AIRT
- ABVC
- Analyst Count
- AIRT 0
- ABVC 0
- Target Price
- AIRT N/A
- ABVC N/A
- AVG Volume (30 Days)
- AIRT 4.1K
- ABVC 223.6K
- Earning Date
- AIRT 08-13-2025
- ABVC 08-13-2025
- Dividend Yield
- AIRT N/A
- ABVC N/A
- EPS Growth
- AIRT N/A
- ABVC N/A
- EPS
- AIRT N/A
- ABVC N/A
- Revenue
- AIRT $296,309,000.00
- ABVC $391,242.00
- Revenue This Year
- AIRT N/A
- ABVC $735.18
- Revenue Next Year
- AIRT N/A
- ABVC N/A
- P/E Ratio
- AIRT N/A
- ABVC N/A
- Revenue Growth
- AIRT 5.14
- ABVC 186.84
- 52 Week Low
- AIRT $14.56
- ABVC $0.40
- 52 Week High
- AIRT $26.70
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- AIRT 50.28
- ABVC 56.53
- Support Level
- AIRT $21.40
- ABVC $2.90
- Resistance Level
- AIRT $22.01
- ABVC $3.06
- Average True Range (ATR)
- AIRT 0.64
- ABVC 0.28
- MACD
- AIRT -0.18
- ABVC 0.00
- Stochastic Oscillator
- AIRT 26.27
- ABVC 91.92
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.